Chris Lau
All posts from Chris Lau
Chris Lau in Value Stocks,

Two Biotech Stocks Too Hot To Handle

Investing in biotech stocks involves watching NDAs, or New Drug Applications. The further away the NDA, the greater the value for the stock in some cases. There are two biotechs to watch.

For Kitov Pharmaceuticals (KTOV), the company’s NDA for its lead product justifies the stock’s ~ 200 percent return. 

KTOV risk: market cap is tiny, but if its marketing application gets clearance, Kitov will have an approved product for 2017.

Celator Pharmaceuticals (CPXX) will file its NDA with the FDA by the third quarter’s end. If VYXEOS’s approval happens, the company may market its product by the third quarter of next year. Celator makes drugs that treat AML, or acute myeloid leukemia.

A Phase 3 data report showed a 60 percent increase in survival. On its conference call, the company said:

“The percentage of patients alive 12 months after randomization was 41.5% on the VYXEOS arm compared to 27.6% on the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% on the VYXEOS arm compared to 12.3% on the 7+3 arm."

More hot biotech ideas